Literature DB >> 9880448

The relationship of hepatotoxic risk factors and liver histology in methotrexate therapy for juvenile rheumatoid arthritis.

P J Hashkes1, W F Balistreri, K E Bove, E T Ballard, M H Passo.   

Abstract

OBJECTIVE: To examine the relationship between hepatotoxic risk factors and liver histopathology in patients with juvenile rheumatoid arthritis (JRA) treated with methotrexate (MTX). STUDY
DESIGN: We graded the histology of 33 percutaneous liver biopsy specimens from 25 patients with JRA treated at Children's Hospital Medical Center, Cincinnati, Ohio, using the Roenigk Classification Scale. Stepwise linear and logistic regression analyses were performed to examine the relationship of the Roenigk grade and presence of liver fibrosis of biopsy specimens with potential risk factors.
RESULTS: Twenty-seven biopsy specimens (82%) were classified as grade I, 4 (12%) as grade II, and 2 (6%) as grade IIIA; none demonstrated significant fibrosis. The frequency of biochemical abnormalities (P <.001) and body mass index (P =.05) were the only risk factors found to significantly relate to the Roenigk grade. The following factors were not significantly associated with the Roenigk grade: age, gender, disease duration, JRA subtype and course, duration of MTX administration, weekly MTX dose, cumulative dose of MTX, route of MTX administration, use of folic acid supplementation, concurrent use of other medications, and potential hepatotoxic comorbidities.
CONCLUSIONS: Serial biochemical abnormalities are significantly associated with Roenigk grade and the presence of liver fibrosis. These findings concur with studies of patients with rheumatoid arthritis, suggesting that guidelines for monitoring MTX hepatotoxicity in rheumatoid arthritis may be applicable to patients with JRA.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9880448     DOI: 10.1016/s0022-3476(99)70371-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  8 in total

Review 1.  Medical management of children with juvenile rheumatoid arthritis.

Authors:  J T Cassidy
Journal:  Drugs       Date:  1999-11       Impact factor: 9.546

Review 2.  [The treatment of juvenile rheumatism: pharmacotherapy].

Authors:  F Weller; H-I Huppertz
Journal:  Z Rheumatol       Date:  2005-06       Impact factor: 1.372

Review 3.  Optimising low-dose methotrexate for rheumatoid arthritis-A review.

Authors:  Catherine J Lucas; Simon B Dimmitt; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2019-08-09       Impact factor: 4.335

4.  Effectiveness and toxicity of methotrexate in juvenile idiopathic arthritis: comparison of 2 initial dosing regimens.

Authors:  Mara L Becker; Carlos D Rosé; Randy Q Cron; David D Sherry; Warren B Bilker; Ebbing Lautenbach
Journal:  J Rheumatol       Date:  2010-03-01       Impact factor: 4.666

5.  Biologic agents for the treatment of juvenile rheumatoid arthritis: current status.

Authors:  Ruy Carrasco; Judith A Smith; Daniel Lovell
Journal:  Paediatr Drugs       Date:  2004       Impact factor: 3.022

Review 6.  Management of drug-induced liver disease.

Authors:  G Marino; H J Zimmerman; J H Lewis
Journal:  Curr Gastroenterol Rep       Date:  2001-02

7.  Methotrexate in sarcoidosis: hematologic and hepatic toxicity encountered in a large cohort over a six year period.

Authors:  Robert P Baughman; Johanna P Cremers; Martina Harmon; Elyse E Lower; Marjolein Drent
Journal:  Sarcoidosis Vasc Diffuse Lung Dis       Date:  2020-09-30       Impact factor: 0.670

8.  Hepascore predicts liver outcomes and all-cause mortality in long-term methotrexate users: A retrospective cohort study.

Authors:  Zhengyi Wang; Yi Huang; Hans Nossent; Jonathan J Chan; Leon A Adams; John Joseph; Wendy Cheng; George Garas; Gerry MacQuillan; Gary P Jeffrey
Journal:  JGH Open       Date:  2020-10-21
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.